Percutaneous Aortic Valve IDE Approval Rests On Clearer Criteria – Edwards
This article was originally published in The Gray Sheet
Executive SummaryEdwards Lifesciences will work with FDA on crafting an acceptable definition for "high-risk patients" to meet an investigational device exemption approval goal of early 2005 for its percutaneous aortic valve, the firm said in a Dec. 3 investor conference
You may also be interested in...
Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.